Bonus Material-18_2025 CHEST Pulmonary Hypertension Board REVIEW_Levine

Pdf Summary

This comprehensive 2025 CHEST Pulmonary Board Review presentation by Dr. Deborah Jo Levine covers Pulmonary Hypertension (PH), focusing on its definition, classification, diagnosis, risk assessment, and management, especially Pulmonary Arterial Hypertension (PAH).<br /><br />PH is a hemodynamic condition defined by a mean pulmonary artery pressure ≥20 mmHg via right heart catheterization (RHC). PH includes diverse clinical groups: Group 1 (PAH), Group 2 (PH due to left heart disease), Group 3 (PH with lung diseases/hypoxia), Group 4 (chronic thromboembolic PH - CTEPH), and Group 5 (unclear/multifactorial mechanisms). The most prevalent categories are Groups 2 and 3 (90-95% of cases).<br /><br />Group 1 PAH includes idiopathic, heritable (notably BMPR2 mutations), drug/toxin associated, connective tissue disease-related (especially scleroderma), HIV, portal hypertension (PoPH), congenital heart disease, and PVOD/PCH subtypes. Diagnosis requires careful clinical, imaging, and hemodynamic evaluation. Echocardiography serves as the best initial screening tool; V/Q scans are essential to rule out CTEPH, which is potentially curable via pulmonary endarterectomy. Definitive diagnosis relies on RHC.<br /><br />Risk stratification using clinical signs, biomarkers (NT-proBNP), exercise testing, echo, and hemodynamics guides management and prognosis. Tools include ESC/ERS guidelines, REVEAL score, and simplified models focused on 1-year mortality risk, aiming to achieve and maintain low-risk status to improve survival.<br /><br />PAH treatment targets endothelial dysfunction via endothelin receptor antagonists (ERAs), phosphodiesterase-5 inhibitors (PDE5i), soluble guanylate cyclase stimulators, prostacyclins, and newer agents like the activin-signaling inhibitor sotatercept, shown to improve clinical outcomes in advanced PAH.<br /><br />Management includes supportive care, close monitoring, and early referral for lung transplantation in high-risk patients. Special considerations apply to groups like scleroderma-PAH, PoPH, and PVOD due to unique risks and poorer prognosis.<br /><br />In summary, PH is a heterogeneous syndrome demanding multidisciplinary evaluation. Accurate classification and hemodynamic assessment guide optimal therapy. Early diagnosis, risk-guided treatment, and integration of emerging therapies and transplant options are critical for improving patient survival.

Meta Tag

Concept Pulmonary Hypertension

Concept Pulmonary Arterial Hypertension

Concept Chronic Thromboembolic Pulmonary Hypertension

Concept Pulmonary Artery Catheterization

Concept Pre-capillary Pulmonary Hypertension

Keywords

pulmonary hypertension

PH

pulmonary arterial hypertension

PAH

right heart catheterization

risk stratification

echocardiography

V/Q scan

CTEPH

endothelin receptor antagonists

sotatercept

lung transplantation

Pulmonary Hypertension

Pulmonary Arterial Hypertension

Chronic Thromboembolic Pulmonary Hypertension

Pulmonary Artery Catheterization

Pre-capillary Pulmonary Hypertension